Effect of micronization on Panax notoginseng: In vitro dissolution & in vivo bioavailability evaluations

Xiao Liang  
Anhui University of Chinese Medicine

Guobing Xu  
Anhui Institute of Food and Drug Control

Zhenbao Li  
Anhui University of Chinese Medicine

Zihua Xuan  
Anhui University of Chinese Medicine

Hongsu Zhao  
Anhui University of Chinese Medicine

Daiyin Peng  
Anhui University of Chinese Medicine

Shuangying Gui (✉ guishy0520@126.com)  
Anhui University of Traditional Chinese Medicine

Research

Keywords: Panax notoginseng powder, particle size, hydrothermal treatment, bioavailability

DOI: https://doi.org/10.21203/rs.3.rs-59582/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** *Panax notoginseng* (PN), the most widely used dietary supplement and herbal in Asian countries. The effect of micronization of PN is not fully clear. The aim of this study was to investigate the effects of the particle size and treatment temperature of *Panax notoginseng* powder (PNP) and the potential to improve the bioavailability.

**Methods:** Several properties of PNP, including the surface morphology and thermal properties were extensively characterized by scanning electron microscopy (SEM), polarized light microscopy (PLM) and differential scanning calorimetry (DSC). The *in vitro* release and *in vivo* bioavailability of *Panax notoginseng* saponins (PNS) were investigated by high-performance liquid chromatography (HPLC) and ultra-high-pressure liquid chromatography-MS/MS (UHPLC-MS/MS).

**Results:** The results showed that particle size reduction significantly change the PNS *in vitro* dissolution and *in vivo* pharmacokinetic. The PNP with a wide size range (from 60 to 214 \(\mu\)m). Several properties of PNP were extensively characterized, these changes of physicochemical properties of PNP provide a better understanding of the *in vitro* and *in vivo* release behaviors of PNS. The *in vitro* studies demonstrated that the dissolution of PNS and particle size was nonlinear (dose- and size-dependent). The pharmacokinetic parameters of PNP in rats were determined by UHPLC-MS/MS. Powder 4 (90.38 ± 8.28 \(\mu\)m) showed significantly higher AUC\(_{0-\text{T}}\) values in plasma \((P<0.05)\). In addition, we also investigated the influence of the hydrothermal treatment of PNP. The results showed that the PNS *in vitro* release and *in vivo* bioavailability were highest of PNP pre-treatment at 40°C.

**Conclusion:** The PNP with a particle size around 90 \(\mu\)m and heat pre-treatment at 40°C would be beneficial.

**Background**

*Panax notoginseng* (PN), the dry root and rhizome of *Panax notoginseng* (Burk.) F.H. Chen, a well-known Traditional Chinese Medicine (TCM) and has a long history in China [1]. PN has definite effects of dispersing blood stasis, hemostasis, detumescence, and analgesia [2]. *Panax notoginseng* saponin (PNS) is one of the key bioactive components of PN [3]. Several studies have shown that PNs possesses various pharmacological activities, such as being antithrombotic, neuroprotective, anti-inflammatory and hypolipidemic etc [4–7]. Besides the medicinal use, PN is also widely used as a functional food in China [8]. PN and PN-based products were listed as an item that can be used as a dietary supplement by the US Dietary Supplement Health and Education Act of 1994 [9–11].

*Panax notoginseng* powder (PNP) is the crushed product of the dry roots of PN, because it was convenient to take and has obvious health care effects, it was favored by people with cardiovascular and cerebrovascular diseases. Substantial studies have demonstrated that the dissolution of the main active ingredients of TCM and its oral bioavailability has often been related to the degree of crushing [12, 13]. Generally, the smaller the particle size is favorable for the dissolution of active ingredients and improving
clinical efficacy [14, 15]. However, there is no uniform size of PNP in the market. Studies have shown that there were significant differences in the dissolution of PN coarse powder, fine powder and micropowder, but micropowder was not better than fine powder in terms of dissolution [16, 17]. In order to systematically investigate the effect of particle size on the dissolution of PNP in vitro, and the correlation between in vitro dissolution and in vivo bioavailability, six types of PNP (from 60 to 214 µm) were prepared in this study. The properties, in vitro dissolution and in vivo bioavailability of PNP with different particle size were investigated, and the effect of the water temperature of the suspension of PNP on its dissolution and absorption, so as to provide a reference for the production specification and usage methods of PNP. We firstly assessed the effects of particle size and hydrothermal treatments on the morphological properties, thermal properties of PNP, and the in vitro dissolution studies were performed in pure water and simulated gastric fluid, and the pharmacokinetics of PNP with different particle sizes and different hydrothermal temperature treatments were performed in rats. Moreover, notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ (the chemical structures of which are shown in Fig. 1C) are considered to be the main components of PNS and were determined in the dissolution and pharmacokinetics studies [18, 19]. The aim of this study was to provide further information to establish guidelines for the use of PNP.

Materials And Methods

Chemicals and materials

The P. notoginseng root was purchased from Anhui Boyao Qiancao Traditional Chinese Medicine Co. Ltd. (Anhui, China) and authenticated by Professor Peng Huasheng (Anhui University of Traditional Chinese Medicine). Pepsin from porcine gastric mucosa was supplied by Yuanye Co. Ltd. (Shanghai, China). The water used was distilled and passed through a Milli-Q water purification system (Millipore, Bedford, USA). All other reagents were of analytical grade or pharmaceutical grade.

Animals

All Sprague Dawley (SD) rats (weight, 250 ± 20 g) were purchased from the Experimental Animal Center of Jinan Pengyue Co. Ltd. (Jinan, China). All animal welfare and experimental procedures were approved by the Animal Ethical Committee of Anhui University of Chinese Medicine (Approval No. 1107261911002543) and were in accordance with the guide for the care and use of laboratory animals. The rats were acclimated for approximately 7 d with a 12 h light and dark cycle throughout the experiment. The rats were housed, given free access to food and water, and the temperature was maintained at room temperature (25°C).

PNP preparation

The PNP was crushed by a highly efficient pulverizer, and the particle size was analyzed using a laser particle size analyzer (BT-9300HT, BAITE, Dandong, China) using water as the dispersion medium.

Characterization of PNP
**Morphological appearance**

The morphological appearance of PNP was observed by scanning electron microscopy (SEM, S3400N HITACHI). The hydrothermal treated samples (Powder 4) were soaked in water for 5 min at 20, 30, 40, 50, 60, 70, 80, 90, or 100°C, respectively, and then the PNP was prepared by freeze drying. The powders were placed on double-sided adhesive tape on SEM stubs with and coated with gold [20].

**Polarized light microscopy (PLM)**

The prepared PNP were characterized by polarization microscope (CK-500, Caikon, China) at room temperature [21]. 500 mg of PNP in a tube was diluted with distilled water (2 mL). The hydrothermal treated samples (Powder 4) were steeped in water for 5 min at 20, 30, 40, 50, 60, 70, 80, 90, or 100°C, respectively.

**Differential scanning calorimetry (DSC)**

The DSC analysis of the PNP was measured using differential scanning calorimetry (DSC200F3, NETZSCH, Germany) under an ultrapure nitrogen atmosphere [22, 23]. The PNP (3 mg) were mixed with 12 μL of distilled water, hermetically sealed in an aluminum pan, and equilibrated at 4°C for 24 h. The scanning temperature was then heated from 20°C to 220°C at a heating rate was 10°C/min.

**Analysis of notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ by HPLC**

The content of notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ in the samples were determined using HPLC and the method reported in the Chinese Pharmacopoeia (2015). HPLC analyses were performed on an Ultimate 3000 series system (Thermo Fisher Scientific, China) consisting of a quaternary pump, DAD detector, and autosampler, and the data were analyzed using Chromeleon 7 software. A Thermo Syncronis C₁₈ column (250 × 4.6 mm, 5.0 μm) was adopted for the separation. The mobile phase consisted of A (pure water) and B (acetonitrile). The gradient mode was as follows: 0 – 12 min, 19% A; 12 – 60 min, 19% ~ 36% A. The flow rate was 1.0 mL/min, and the detection wavelength was set to 203 nm. The column temperature was 25°C, and the sample injection volume was set to 20 μL.

**In vitro dissolution studies**

The effects of particle size and hydrothermal treatment (Powder 4 were treated at 30, 40, 50, and 100°C) on the dissolution behavior of the PNP were investigated. Dissolution studies were carried out on a dissolution apparatus (ZRS-8L, Tianda Tianfa, China) with a rotation speed of 75 rpm according to the China Pharmacopoeia apparatus paddle method [24, 25]. The tests were performed in 150 mL of freshly prepared aqueous solution and simulated gastric fluid (10 g/L pepsin, 0.1 M HCL, pH = 1.2, ChP 2015). Maintaining a temperature of 37 ± 0.5°C, samples of 4 mL each were withdrawn and replaced with fresh medium of equal volume at fixed time points of 0, 5, 10, 15, 20, 25, 30, 60, 90, and 180 min, respectively. The content of notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ in the medium were determined by
HPLC as described above. Because the dissolution of ingredients was affected by the particle size, the dissolution rate calculated using the revised equation is as follow:

\[
\text{Dissolution}\% = \frac{V \sum_{i=1}^{n} C_i + V_0 C_n}{m_{PNP}} \times 100%
\]

In this formula, \( V_e \) means 4 mL, \( C_i \) means the sample concentration of release medium from the ith permutation, \( V_0 \) means the total volume of release medium, \( n \) means the number of replacement release medium, \( m_{PNP} \) means the weight of PNP.

**In vivo pharmacokinetic study**

Before administration, sixty rats were fasted for 12 h, but free access to water. The rats were randomly divided into ten groups, six rats in each group. Rats were pretreated with different particle sizes of PNP (Powders 1 ~ 6, 540 mg/kg, i.g.) or the PNP (Powder 4) treated at different temperatures (30, 40, 50, and 100°C, 540 mg/kg, i.g.). After intragastric administration of PNP, 200 µL of blood was collected into heparinized tubes, at 0.08, 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 12, 24, 48 h from the ophthalmic veins and centrifuged at 3000 rpm for 10 min. Plasma was separated and frozen at -20°C for analysis. 10 µL of digoxin (1.0 µg/mL) as an internal standard (IS) was added to each blood sample (100 µL), which was pretreated according to the previously published method [26], and the concentrations of notoginsenosides were analyzed using a validated UHPLC-MS/MS method.

The notoginsenosides in the biological samples were analyzed using a validated UHPLC-MS/MS method. The UHPLC-MS/MS system (UHPLC-MS/MS-5500 system, AB Sciex Instrument, USA) contained an ExionLC AD UHPLC system and a QTRAP 5500 triple quadrupole mass spectrometry instrument equipped with an electron spray ionization (ESI) source. The data acquisition and analysis were performed using MultiQuant software (AB Sciex Instrument). Liquid chromatographic separation was carried out at 25°C using a 1.8 µm, 100 × 2.1 mm Epic C18 column. The mobile phase was composed of acetonitrile (solvent A) and water containing 0.1 mM ammonium chloride (solvent B). An optimized gradient elution condition was set as 10% A (0 ~ 0.02 min), 10% ~ 75% A (0.02 ~ 5 min), 75% A (5 ~ 5.5 min), 75% ~ 10% A (5.5 ~ 6 min), and 10% A (6 ~ 9 min). A sample volume of 2 µL was injected, and a flow rate of 0.2 mL/min was employed. The ESI source was operated in negative ionization mode, and the MS conditions were set as follows: desolvation temperature, 250°C; heat block temperature, 550°C; nebulizer gas flow, 3 L/min; drying gas flow, 15 L/min; and interface voltage, 3.5 kV. Data were acquired by multiple reaction monitoring (MRM). Table 1 lists the quantitatively optimized parameters, including the declustering potential (DP), collision energy (CE), etc.

**Statistical analysis**

All data are expressed as the mean ± SD. Differences between groups were compared by SPSS Statistics 24 using the independent-samples t-test or paired-samples t-test. Statistically significant differences were determined at \( P < 0.05 \) and \( P < 0.01 \).
Results And Discussion

Particle size and morphological properties of PNP

The particle size measurements in Table 2 and the size distribution of the PNP varied significantly. The morphologies of the different particle sizes and hydrothermal treated PNP was observed by naked eyes and SEM and under polarized light (Figure 1A). The PNP appeared in grayish yellow and with the particle size decreased, the PNP tended to become disrupted and aggregate. The PNP had the birefringence characteristic (Maltese cross) of the starch granules when viewed using polarized light, and as the particle size of the PNP decreased, the Maltese cross of the starch granules became increasingly obvious. During heating, as shown in Figure 1B, at temperatures above 50°C, the birefringence gradually disappeared. Micromorphological characteristics of the PNP and heat-treated PNP at 20 to 100°C were further observed using SEM. During heating, the PNP maintained a granular morphology until the temperature reached 50°C; above this temperature, the PNP gradually absorbed water, expanded in the radial direction and formed a cross-linked structure. Eventually, all the PNP melted and fused into large aggregates.

Thermal properties

The gelatinization of PNP is important in active ingredient release, and DSC is the most accepted way to measure gelatinization temperatures [22, 23, 27, 28]. The gelatinization temperatures of PNP were 40.03 ~ 46.87°C, 113.41 ~ 115.77°C and 121.12 ~ 122.55°C for the onset temperature of gelatinization (T_o), the peak temperature (T_p) and the conclusion temperature (T_c), respectively (Table 3). These results indicate that the onset temperature of gelatinization of PNP was in the range of 40 ~ 50°C, and the gelatinization property could be independent of granule size.

In vitro dissolution study

The effects of particle size and temperature on saponin dissolution are shown in Figures 2. The tests were carried out in aqueous solution (Figure 2A-H) and simulated gastric uid (Figure 2a-h). The notoginsenoside R1 and ginsenosides Rg1 and Rb1 release from the PNP with different particle sizes (Powders 1 ~ 6) and the hydrothermal treated PNP at different temperatures (30, 40, 50 and 100°C) were comparable. From Figure 2A-D, the PNP showed a high dissolution rate with > 90% of the saponins released within 30 min. The dissolution of the saponins from Powder 1 was higher than that of the other powders, while the dissolution of the saponins from Powder 6 was the lowest. The dissolution results showed that the dissolution behavior of notoginsenoside R1 and ginsenosides Rg1 and Rb1 could be independent of particle size. As the particle size decreased to a certain extent (such as in Powder 6), the saponins also decreased (the PNS decreased from 90.51 to 76.51 mg/g compared with Powder 1), and the peak of the PNS from Powder 1 and Powder 6 was statistically significant (P< 0.05). The effects of temperature are shown in Figure 2E-H. The amount of saponins contained in the PNP treated at 40°C was higher than that of the other temperatures. Combined with the SEM and DSC results, it can be inferred that the starch granules from the PNP treated at 30°C and 40°C were in the gelatinization process of
water absorption [21]. At this stage, the water molecules enter the starch granule gap in the PNP, a small amount of water is absorbed by the starch granules, and the swelling makes the active ingredients in the PNP more soluble. Upon heating and entering the gelatinization temperature, the samples enter the irreversible water absorption stage, and so the PNP treated at 50°C and 100°C were at this stage, and a large amount of water was quickly absorbed by the starch granules, causing the granules swell to 600% ~ 1000% of their original volume [29]. Meanwhile, the swollen PNP aggregated and formed a cross-linked structure (Figure 1B), resulting in the active ingredient being difficult to dissolve. In the daily use of PNP, the maximum temperature of water consumption is 100°C, so further increasing temperatures were not studied.

From Figure 2a-d, Powder 1 (released for 180 min) showed the sustained release of notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ with a statistically significant difference (P < 0.01) compared to Powder 6. Notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ are extremely unstable in simulated gastric fluid, which was in agreement with results previously reported [30-32]. The maximum dissolution of PNP with different particle sizes in simulated gastric fluid was lower than that when water was used as the release medium, but the peak time in simulated gastric fluid was earlier than that of water. The dissolution of the saponins contained in the PNP at 40°C was higher than that of the other temperatures (Figure 2e-h). The maximum dissolution of notoginsenoside R₁ was 1.11-, 1.88- and 5.28-fold greater than that of the other temperature groups (30, 50, and 100°C, respectively). Ginsenoside Rg₁ was 1.21-, 1.87-, and 6.09-fold greater than that of the other temperature groups, and ginsenoside Rb₁ was 1.12-, 1.47-, and 3.06-fold greater than that of the other temperature groups, respectively. From Figure 2e-h, the dissolution of PNP showed a high dissolution rate with > 90% of the saponins released within 10 min, which may be because the degradation rate of the saponins in the gastric juice environment is higher than the dissolution rate.

In vivo study

The UHPLC-MS/MS methods were subjected to validation based on specificity, linearity, sensitivity, intraday and interday precision, accuracy, recovery, matrix effect, and stability. The specificity was analyzed by comparing chromatograms of blank plasma (from 6 different rats), blank plasma with IS, notoginsenoside R₁, ginsenosides Rg₁ and Rb₁, and plasma samples after intragastric administration of PNP. As shown in Figure 3A-C, there was no significant endogenous peak interference within the retention time of the IS, notoginsenoside R₁, or ginsenosides Rg₁ and Rb₁. The linearity of the calibration curves was found to be high in the range of 0.9996 ~ 499.8 ng/mL for notoginsenoside R₁ (r = 0.9991), 0.9744 ~ 487.2 ng/mL for ginsenoside Rg₁ (r = 0.9947), 1.0843 ~ 541.8 ng/mL for ginsenoside Rb₁ (r = 0.9991). The intra- and interday precisions of notoginsenoside R₁ and ginsenosides Rg₁ and Rb₁ in rat plasma were less than 15% in terms of RSD%, and the accuracy was below 20% in terms of RE%. The recovery value for notoginsenoside R₁ was 83.67% at 4.998 ng/mL, 84.44% at 49.98 ng/mL and 93.56% at 199.9 ng/mL; for ginsenoside Rg₁, the recoveries were 76.86% at 4.887 ng/mL, 88.64% at 48.72 ng/mL and 85.57% at 194.9 ng/mL; for ginsenoside Rb₁, the recoveries were 73.64% at 5.468 ng/mL, 91.05% at
54.18 ng/mL and 82.66% at 216.7 ng/mL; and the standard deviations (SD) were all lower than 7.23%. This method was suggested to be high-throughput and reliable.

The mean plasma concentration-time curves after oral administration of PNP of different sizes and hydrothermal treated treatments are shown in Figure 3. The pharmacokinetic parameters are listed in Tables 4 and 5. From Figure 3a-c and Table 4, the results show that the AUC$_{0-T}$ of the three saponins in Powder 4 were significantly higher than in the other powders ($P < 0.05$), and the AUC$_{0-T}$ of notoginsenoside R$_1$ is 6.21-fold greater than that of Powder 1 and 13.31-fold that of Powder 6. The AUC$_{0-T}$ of ginsenoside Rg$_1$ from Powder 4 is 5.69-fold that of Powder 1 and 15.69-fold that of Powder 6. Finally, the AUC$_{0-T}$ of ginsenoside Rb$_1$ from Powder 4 is 6.2-fold that of Powder 1 and 13.3-fold that of Powder 6. The results showed that after intragastric administration of Powder 4, the concentrations of notoginsenoside R$_1$ and ginsenosides Rg$_1$ and Rb$_1$ in systemic circulation were higher than those of the other powders. The T$_{max}$ values of the three saponins from Powder 5 were much smaller than those of the other powders, and the C$_{max}$ of ginsenoside Rg$_1$ was higher than that of other powders, indicating that after the administration of Powder 5, the saponins are absorbed quickly in the body and reach a peak rapidly. After Powders 4 and 5 were administered by intragastric administration, notoginsenoside R$_1$ and ginsenosides Rg$_1$ and Rb$_1$ exhibited double peaks in the C-T figures (Powder 4 was more obvious), which were consistent with results previously reported [21, 33]. This result could be due to differential rates of absorption along the gastrointestinal tract, and this prolonged residence time of the drug in the body could be beneficial to the maintenance of the drug effect, but the mechanisms of the double peaks remain to be determined [34, 35]. The data suggested that the decrease in particle size can successfully improve the bioavailability within a range of 213.93 ~ 90.38 μm ( Powders 1 ~ 4), and the result was not in agreement with the dissolution data (Figure 2a-d). This phenomenon could be related to the high concentration of ginsenosides having a tendency to form self-micelles that might prevent them from permeation and absorption [36].

Figure 3d-f and Table 5 show that the AUC$_{0-\infty}$ of notoginsenoside R$_1$ and ginsenoside Rg$_1$ after the administration of the 40°C-treated PNP were 3.33, 1.95, 7.59-fold and 3.27, 1.45, 5.59-fold greater than at 30, 50 and 100°C, respectively. The AUC$_{0-\infty}$ of ginsenoside Rb$_1$ after the administration of PNP at 50°C was 9.29, 1.68 and 2.47-fold that at 30, 40 and 100°C, respectively. This result was in good agreement with the dissolution data, that the higher dissolution in vitro led to faster absorption in vivo. It could be concluded that temperature can affect the absorption of saponins, and the highest bioavailability of PNP was after treatment at 40°C.

**Conclusion**

This work confirmed that the micronization of PN and hydrothermal treatment had a significant effect on the properties and in vitro & in vivo behavior of PNP. In vitro studies have shown that the amount and rate of dissolution of saponins are independent of the particle size in the range of 213.93 to 59.89 μm, but the hydrothermal PNP at different temperatures could affect the dissolution of saponins (40°C was the most
The bioavailability of Powder 4 (90.38 ± 8.28 μm) was better than the other particle size powders, and it was found that Powder 4 was the easiest to prepare during the preparation process. The bioavailability of PNP after treatment at 40°C was the highest. In summary, it is recommended to use PNP with a particle size around 90 μm and suspend in 40°C water.

Declarations

Acknowledgements

Not applicable.

Authors’ contributions

XL carried out the screening experiments, drafted the manuscript and analyzed the data. GBX, ZBL and SYG contributed to the design and interpretation of the research. ZHX and HSZ analyzed data. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81873019).

Availability of data and materials

The research data generated from this study is included within the article.

Ethics approval and consent to participate

This study was approved by the Animal Ethic Committee of Anhui University of Chinese Medicine (Approval No. 1107261911002543).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Anhui University of Chinese Medicine, Hefei, China. 2 Anhui Institute for Food and Drug Control, Hefei, China. 3 Key Laboratory of Xin’an Medicine, Anhui University of Chinese Medicine, Ministry of Education, Hefei, China. 4 Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China. 5 Anhui Province Key Laboratory of Pharmaceutical Technology and Application, Anhui University of Chinese Medicine.
Medicine, Hefei, China. Engineering Technology Research Center of Modernized Pharmaceutics, Education Office of Anhui Province, Hefei, China.

**Abbreviations**

DSC, differential scanning calorimetry; HPLC, high-performance liquid chromatography; PLM, polarized light microscopy; PN, *Panax notoginseng*; PNP, *Panax notoginseng* powder; PNS, *Panax notoginseng* sapoins; SEM, scanning electron microscopy; TCMs, Traditional Chinese Medicines; UHPLC-MS/MS, ultra-high-pressure liquid chromatography-MS/MS.

**References**

1. Dong TT, Cui XM, Song ZH, Zhao KJ, Ji ZN, Lo CK, et al. Chemical assessment of roots of *Panax notoginseng* in China: regional and seasonal variations in its active constituents. J Agric Food Chem. 2003;51:4617–23.

2. Briskin DP. Medicinal Plants and Phytomedicines. Linking Plant Biochemistry and Physiology to Human Health. Plant Physiol. 2000;124:507–14.

3. He N, Zhao Y, Guo L, Shang J, Yang X. Antioxidant, Antiproliferative, and Pro-Apoptotic Activities of a Saponin Extract Derived from the Roots of *Panax notoginseng* (Burk.) F.H. Chen. J Med Food. 2012;15:35–59.

4. Xia W, Sun C, Zhao Y, Wu L. Hypolipidemic and antioxidant activities of Sanchi (Radix Notoginseng) in rats fed with a high fat diet. Phytomedicine. 2011;18:516–20.

5. Huang J, Feng Y, Bai L, Qin M, Xu Z, Liu Z, et al. Fraction n-Butanol of Radix Notoginseng Protects PC12 Cells from Aβ25–35-Induced Cytotoxicity and Alleviates Cognitive Deficits in SAMP8 Mice by Attenuating Oxidative Stress and Aβ Accumulation. Evidence-Based Complementary and Alternative Medicine; 2017;2017:1–10.

6. Son HY, Han HS, Jung HW, Park Y. *Panax notoginseng* Attenuates the Infarct Volume in Rat Ischemic Brain and the Inflammatory Response of Microglia. Journal of Pharmacological Sciences. 2009;109:368–79.

7. Wang YL, Chen D, Wu JL. Effects and mechanism of total saponins of Panax Notoginseng on anti-inflammation and analgesia. Chinese Journal of Integrated Traditional Western Medicine. 1994;14:35.

8. Yang Y. Scientific substantiation of functional food health claims in China. The Journal of Nutrition. 2008;138:1199S–1205S.

9. Young AL, Bass IS. The Dietary Supplement Health and Education Act. Food Drug Law Journal. 1995;50:285.

10. Xiong Y, Chen L, Man J, Hu Y, Cui X. Chemical and bioactive comparison of *Panax notoginseng* root and rhizome in raw and steamed forms. J Ginseng Res. 2019;43:385–93.
11. Xiong Y, Chen L, Hu Y, Cui X. Uncovering Active Constituents Responsible for Different Activities of Raw and Steamed Panax notoginseng Roots. Front Pharmacol. 2017;8:745.
12. Liu J, Guo H, Xiao J, Wen L, Chen L, Chen H, et al. Comparison of Micromeritics Properties and in Vitro Dissolution of Bletillae Rhizoma Powder with Different Particle Size. Chinese Journal of Experimental Traditional Medical Formulate. 2018;24:25–9.
13. Li W, Li Q, Zhang H. Comparison of Dissolution of Shenli Powder Fine Powder and Its Different Particle Size Ultrafine Powder. Guiding Journal of Traditional Chinese Medicine Pharmacology. 2016;22:58–9.
14. Zhang B, Li X, Xie Q, Tao H, Wang W, Chen HQ. Preparation and characterization of non-crystalline granular starch and corresponding carboxymethyl starch. Int J Biol Macromol. 2017;103:656–62.
15. Liu PL, Zhang BS, Shen Q, Hu XS, Li WH. Preparation and structure analysis of noncrystalline granular starch. Int J Food Eng. 2010;6:61–4.
16. Li. Dan-hui WYLH. Comparison of in Situ Intestinal Absorption in Rats of Saponins in Three Kinds of Notoginseng Radix et Rhizoma Samples. China Journal of Experimental Traditional Medical Formulae. 2017;23:10–4.
17. Wu X, Liang S, Cheng W, Wang T. Comparison on in vitro dissolution behavior of notoginsenoside R1, ginsenosides Rb1 and Rg1 between ordinary fine and ultrafine powder of Panax notoginseng. Chinese Traditional Herbal Drugs. 2013;44:3489–92.
18. WANG YU, FENG YU, FU Q. LI L. Panax notoginsenoside Rb1 ameliorates Alzheimer's disease by upregulating brain-derived neurotrophic factor and downregulating Tau protein expression. Experimental Therapeutic Medicine. 2013;6:826–30.
19. Guo Q, Li P, Wang Z, Cheng Y, Wu H, Yang B, et al. Brain distribution pharmacokinetics and integrated pharmacokinetics of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of Panax Notoginseng Saponins assessed by UPLC/MS/MS. J Chromatogr B. 2014;969:264–71.
20. Benyerbah N, Ispas-Szabo P, Sakeer K, Chapdelaine D, Mateescu MA. Ampholytic and Polyelectrolytic Starch as Matrices for Controlled Drug Delivery. Pharmaceutics. 2019;11:253.
21. Chen L, Tian Y, McClements DJ, Huang M, Zhu B, Wang L, et al. A simple and green method for preparation of non-crystalline granular starch through controlled gelatinization. Food Chem. 2019;274:268–73.
22. Li MN, Xie Y, Chen HQ, Zhang B. Effects of heat-moisture treatment after citric acid esterification on structural properties and digestibility of wheat starch, A- and B-type starch granules. Food Chem. 2019;272:523–9.
23. Xia T, Gou M, Zhang G, Li W, Jiang H. Physical and structural properties of potato starch modified by dielectric treatment with different moisture content. Int J Biol Macromol. 2018;118:1455–62.
24. Ma Q, Wang C, Li X, Guo H, Meng J, Liu J, et al. Fabrication of water-soluble polymer-encapsulated As4S4 to increase oral bioavailability and chemotherapeutic efficacy in AML mice. Sci Rep. 2016;6:29348.
25. Kwon HJ, Heo E, Kim Y, Kim S, Hwang Y, Byun J, et al. Development and Evaluation of Poorly Water-Soluble Celecoxib as Solid Dispersions Containing Nonionic Surfactants Using Fluidized-Bed Granulation. Pharmaceutics. 2019;11:136.

26. Zhou L, Xing R, Xie L, Rao T, Wang Q, Ye W, et al. Development and validation of an UFLC-MS/MS assay for the absolute quantitation of nine notoginsenosides in rat plasma: Application to the pharmacokinetic study of Panax Notoginseng Extract. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;995–996:46–53.

27. Paraginski RT, Colussi R, Dias A, Da RZE, Elias MC, Vanier NL. Physicochemical, pasting, crystallinity, and morphological properties of starches isolated from maize kernels exhibiting different types of defects. Food Chem. 2019;274:330–6.

28. Yong H, Wang X, Sun J, Fang Y, Liu J, Jin C. Comparison of the structural characterization and physicochemical properties of starches from seven purple sweet potato varieties cultivated in China. Int J Biol Macromol. 2018;120:1632–8.

29. Belitz. *Food chemistry*. 2009;Springer.

30. Guo YP, Chen MY, Shao L, Zhang W, Rao T, Zhou HH, et al. Quantification of Panax notoginseng saponins metabolites in rat plasma with in vivo gut microbiota-mediated biotransformation by HPLC-MS/MS. Chin J Nat Med. 2019;17:231–40.

31. Feng H, Chen W, Zhu C. Pharmacokinetics study of bio-adhesive tablet of Panax notoginseng saponins. Int Arch Med. 2011;4:18.

32. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol. 2003;84:187–92.

33. Zhu D, Zhou Q, Li H, Li S, Dong Z, Li D, et al. Pharmacokinetic Characteristics of Steamed Notoginseng by an Efficient LC-MS/MS Method for Simultaneously Quantifying Twenty-three Triterpenoids. J Agric Food Chem. 2018;66:8187–98.

34. Helmy SA. Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. Biopharm Drug Dispos. 2013;34:288–301.

35. Burda T, Sigg T. Double peak and prolonged absorption after large acetaminophen extended release and diphenhydramine ingestion. Am J Ther. 2012;19:e101–4.

36. Xiong J, Guo J, Huang L, Meng B, Ping Q. Self-micelle formation and the incorporation of lipid in the formulation affect the intestinal absorption of Panax notoginseng. Int J Pharm. 2008;360:191–6.

**Tables**

**Table 1.** MRM parameters of notoginsenosides and internal standard.
| Analyte | Precursor (m/z) | Product (m/z) | CE (eV) | DP (eV) |
|---------|----------------|---------------|----------|---------|
| R₁      | 967.7          | 637.5         | -22      | -46     |
| Rg₁     | 835.7          | 637.4         | -138     | -55     |
| Rb₁     | 1143.7         | 1107.7        | -294     | -59     |
| IS      | 815.5          | 779.4         | -82      | -35     |

Table 2. The particle sizes of PNP (n=3).

| Sample  | Particle size (μm) |
|---------|--------------------|
| Powder 1| 213.93 ± 7.06      |
| Powder 2| 170.02 ± 2.72      |
| Powder 3| 103.77 ± 2.78      |
| Powder 4| 90.38 ± 8.28       |
| Powder 5| 72.77 ± 0.13       |
| Powder 6| 59.89 ± 0.06       |

Table 3. Thermal parameters of the PNP (n = 3).

| Sample  | T₀ (°C)    | Tₚ (°C)    | Tₐ (°C)    |
|---------|------------|------------|------------|
| Powder 1| 46.87 ± 5.50 | 114.70 ± 1.50 | 122.14 ± 0.79 |
| Powder 2| 45.38 ± 4.36 | 115.66 ± 1.53 | 122.29 ± 2.28 |
| Powder 3| 42.02 ± 4.82 | 115.07 ± 3.64 | 122.55 ± 3.05 |
| Powder 4| 40.03 ± 3.59 | 115.70 ± 1.51 | 122.34 ± 2.27 |
| Powder 5| 45.33 ± 2.02 | 113.41 ± 4.93 | 121.12 ± 2.80 |
| Powder 6| 40.74 ± 4.05 | 115.77 ± 1.55 | 122.50 ± 1.40 |

Table 4. The pharmacokinetic parameters of notoginsenosides following the intragastric administration of 540 mg/kg PNP (n = 6), samples 1 ~ 6 correspond to Powders 1 ~ 6.
| Notoginsenoside | Sample | $C_{\text{max}}$ (ng/mL) | $T_{\text{max}}$ (h) | $t_{1/2}$ (h) | MRT (h) | AUC$_{0-T}$ (ng·h/mL) | AUC$_{0-\infty}$ (ng·h/mL) |
|----------------|--------|---------------------------|---------------------|-------------|--------|---------------------|---------------------|
| $R_1$          | 1      | 96.77 ± 8.33              | 0.75 ± 0.43         | 61.40 ± 24.40 | 24.39 ± 0.28** | 3927.74 ± 168.19** | 15934.90 ± 3756.68  |
|                | 2      | 214.85 ± 46.16            | 18.67 ± 8.64        | 30.85 ± 17.86 | 25.56 ± 1.18**  | 7988.59 ± 1539.43** | 22347.20 ± 3962.25* |
|                | 3      | 480.12 ± 184.33           | 1.31 ± 0.91         | 45.18 ± 19.94 | 23.28 ± 1.62**  | 10703.32 ± 195.88** | 26067.99 ± 2653.31** |
|                | 4      | 2520.17 ± 699.78          | 1.83 ± 1.68         | 10.83 ± 5.83** | 20.42 ± 0.76**  | 24392.12 ± 1209.31** | 25608.71 ± 963.71**  |
|                | 5      | 1325 ± 70.20              | 0.15 ± 0.03         | 11.01 ± 0.13*  | 10.58 ± 0.19**  | 5136.15 ± 139.26**  | 6490.01 ± 2116.24   |
|                | 6      | 585.16 ± 113.86           | 0.92 ± 0.30         | 58.53 ± 29.21  | 16.55 ± 1.66    | 1832.64 ± 147.30    | 4246.85 ± 1457.93   |
| $R_g_1$        | 1      | 1078.91 ± 221.73          | 0.43 ± 0.15         | 22.28 ± 17.71  | 13.64 ± 1.25**  | 14876.10 ± 3408.79  | 44835.03 ± 14993.19 |
|                | 2      | 1997.5 ± 325.40           | 0.96 ± 0.10         | 17.02 ± 3.81   | 19.36 ± 2.01**  | 33292.35 ± 6663.89** | 58485.02 ± 38882.91* |
|                | 3      | 1577.33 ± 8.17            | 1.17 ± 0.41         | 57.43 ± 24.07** | 23.30 ± 2.23**  | 26219.02 ± 2116.79** | 73657.82 ± 31451.60** |
|                | 4      | 10134.52 ± 4812.27        | 1.83 ± 1.68         | 7.72 ± 0.83**  | 23.04 ± 1.70**  | 84696.89 ± 13040.28** | 85766.94 ± 12948.66** |
|                | 5      | 10590 ± 230.56            | 0.29 ± 0.10**       | 3.52 ± 0.72    | 8.72 ± 0.38**   | 23225.07 ± 2017.82** | 23433.90 ± 1935.81  |
|                | 6      | 2270.72 ± 670.85          | 1.04 ± 0.25         | 5.78 ± 1.29    | 4.7 ± 0.36      | 5396.88 ± 349.55     | 5763.17 ± 335.36    |
| $R_b_1$        | 1      | 9.84 ± 4.99*              | 36 ± 13.14**        | 42.00 ± 24.07  | 28.69 ± 3.80**  | 296.79 ± 85.85**     | 770.01 ± 225.94     |
|                | 2      | 64.52 ± 27.33*            | 22.00 ± 4.90        | 11.17 ± 5.32   | 29.65 ±        | 1756.56 ± 634.27**   | 2115.94 ± 361.33    |
| Sample | AUC 0-24h (μg·h·mL⁻¹) | Tmax (h) | Cmax (μg·mL⁻¹) | T1/2 (h) | C0.73 (μg·mL⁻¹) |
|--------|------------------------|----------|----------------|----------|-----------------|
| 3      | 76.90 ± 9.97           | 18.00 ± 8.49 | 83.46 ± 52.21 | 22.57 ± 1.00 | 2444.21 ± 100.46 | 7518.63 ± 3769.97 |
| 4      | 741.18 ± 408.39        | 2.05 ± 1.78 | 12.37 ± 7.81* | 18.33 ± 1.17 | 7212.91 ± 169.41** | 10109.07 ± 4381.42 |
| 5      | 331.05 ± 16.35         | 0.15 ± 0.03 | 10.85 ± 2.52* | 11.50 ± 0.32** | 2031.16 ± 61.08** | 2160.99 ± 71.61 |
| 6      | 140.71 ± 21.88         | 0.79 ± 0.37 | 56.67 ± 31.54 | 18.56 ± 1.29 | 1068.46 ± 179.46 | 2388.17 ± 841.41 |

*P < 0.05, **P < 0.01, versus Powder 6.

**Table 5.** The pharmacokinetic parameters of notoginsenosides following 540 mg/kg intragastric administration of PNP treated at different temperatures (n = 6); sample 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.
| Notoginsenoside | Sample | $C_{\text{max}}$ (ng/mL) | $T_{\text{max}}$ (h) | $t_{1/2}$ (h) | MRT (h) | $\text{AUC}_{0-T}$ (ng h/mL) | $\text{AUC}_{0-\infty}$ (ng h/mL) |
|----------------|--------|--------------------------|-------------------|-------------|--------|---------------------------|-----------------------------|
| $R_1$          | 30°C   | 572.15 ± 3.00            | 5.67 ± 0.82       | 7.99 ± 3.92 | 17.77 ± 1.70* | 7580.39 ± 1242.09         | 7716.85 ± 1259.98         |
|                | 40°C   | 1390.85 ± 652.91*       | 0.54 ± 0.10       | 49.37 ± 22.02  | 20.35 ± 1.27** | 13164.57 ± 1381.68**      | 25703.83 ± 5377.46**       |
|                | 50°C   | 796.67 ± 98.29          | 1.93 ± 1.26       | 6.21 ± 0.32*  | 17.27 ± 0.75   | 12599.54 ± 1698.24**       | 13159.87 ± 1263.91        |
|                | 100°C  | 824.20 ± 86.07          | 1.33 ± 0.52       | 42.03 ± 27.99 | 8.62 ± 0.65    | 2580.91 ± 378.24           | 3388.29 ± 951.55          |
| $Rg_1$         | 30°C   | 4223.25 ± 5.32*         | 0.23 ± 0.05*      | 4.31 ± 0.54   | 9.37 ± 1.38    | 14825.41 ± 1107.87         | 17920.93 ± 2148.99        |
|                | 40°C   | 4469.58 ± 2181.84       | 0.46 ± 0.10       | 30.04 ± 13.17 | 18.75 ± 0.97** | 39965.99 ± 4336.01**       | 58687.93 ± 12288.43**      |
|                | 50°C   | 2982.75 ± 610.15        | 2.01 ± 1.24       | 4.51 ± 0.44   | 15.81 ± 0.96** | 40506.20 ± 6170.47**       | 40542.23 ± 6159.83*        |
|                | 100°C  | 2665.42 ± 378.99        | 1.33 ± 0.52       | 7.13 ± 4.56   | 9.51 ± 0.84    | 10354.88 ± 1599.79         | 10495.51 ± 1490.15        |
| $Rb_1$         | 30°C   | 245.16 ± 62.15          | 1.17 ± 0.41       | 8.51 ± 7.08*  | 15.60 ± 2.63  | 1951.25 ± 358.41**         | 2619.71 ± 1138.15         |
|                | 40°C   | 295.87 ± 82.18          | 0.54 ± 0.10**     | 36.26 ± 5.61  | 22.05 ± 1.09** | 6462.73 ± 830.14           | 14491.60 ± 7236.11        |
|                | 50°C   | 381.11 ± 158.24         | 2.67 ± 1.03       | 21.15 ± 13.78 | 21.15 ± 1.29  | 9138.96 ± 3314.69*         | 24329.15 ± 14404.06       |
|                | 100°C  | 345.88 ± 51.91          | 10.17 ± 4.49      | 35.85 ± 15.84 | 14.49 ± 6.22  | 6103.76 ± 328.86           | 9846.49 ± 1855.47         |

*P < 0.05, **P < 0.01, versus 100°C.

Figures
Figure 1

A. Morphological appearance and PLM images of the PNP with different particle sizes, B. SEM and PLM images of the hydrothermal treated PNP, C Structure of notoginsenoside R1 and ginsenosides Rg1 and Rb1.
Figure 1

A. Morphological appearance and PLM images of the PNP with different particle sizes, B. SEM and PLM images of the hydrothermal treated PNP, C. Structure of notoginsenoside R1 and ginsenosides Rg1 and Rb1.
Figure 1

A. Morphological appearance and PLM images of the PNP with different particle sizes, B. SEM and PLM images of the hydrothermal treated PNP, C Structure of notoginsenoside R1 and ginsenosides Rg1 and Rb1.
Figure 2

Dissolution profiles of the PNP in pure water (A ~ H) and simulated gastric fluid (a ~ h). A, E, a, e: Notoginsenoside R1; B, F, b, f: Ginsenosides Rg1; C, G, c, g: Ginsenosides Rb1; D, H, d, h: PNS. 1 ~ 6 correspond to Powders 1 ~ 6, and 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.
Figure 2

Dissolution profiles of the PNP in pure water (A ~ H) and simulated gastric fluid (a ~ h). A, E, a, e: Notoginsenoside R1; B, F, b, f: Ginsenosides Rg1; C, G, c, g: Ginsenosides Rb1; D, H, d, h: PNS. 1 ~ 6 correspond to Powders 1 ~ 6, and 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.
Figure 2

Dissolution profiles of the PNP in pure water (A ~ H) and simulated gastric fluid (a ~ h). A, E, a, e: Notoginsenoside R1; B, F, b, f: Ginsenosides Rg1; C, G, c, g: Ginsenosides Rb1; D, H, d, h: PNS. 1 ~ 6 correspond to Powders 1 ~ 6, and 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.
Figure 3

MRM chromatograms and the plasma concentration-time profiles of notoginsenoside R1, Rg1, and Rb1 in rats following intragastric administration of different sizes of PNP at a dose of 540 mg/kg. A: Blank rat plasma, B: Blank plasma spiked with notoginsenosides and IS, C: Rat plasma collected at 30 min after intragastric administration of 540 mg/kg PNP. a, d: Notoginsenoside R1, b, e: Ginsenosides Rg1, c, f: Ginsenosides Rb1. Samples 1 ~ 6 correspond to Powders 1 ~ 6, and 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.
Figure 3

MRM chromatograms and the plasma concentration-time profiles of notoginsenoside R1, Rg1, and Rb1 in rats following intragastric administration of different sizes of PNP at a dose of 540 mg/kg. A: Blank rat plasma, B: Blank plasma spiked with notoginsenosides and IS, C: Rat plasma collected at 30 min after intragastric administration of 540 mg/kg PNP. a, d: Notoginsenoside R1, b, e: Ginsenosides Rg1, c, f: Ginsenosides Rb1. Samples 1 ~ 6 correspond to Powders 1 ~ 6, and 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.
Figure 3

MRM chromatograms and the plasma concentration-time profiles of notoginsenoside R1, Rg1, and Rb1 in rats following intragastric administration of different sizes of PNP at a dose of 540 mg/kg. A: Blank rat plasma, B: Blank plasma spiked with notoginsenosides and IS, C: Rat plasma collected at 30 min after intragastric administration of 540 mg/kg PNP. a, d: Notoginsenoside R1, b, e: Ginsenosides Rg1, c, f: Ginsenosides Rb1. Samples 1 ~ 6 correspond to Powders 1 ~ 6, and 30, 40, 50, 100°C correspond to the PNP treated at different hydrothermal temperatures.